AST SpaceMobile R&D decreased by 21.3% to $7.13M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.1%, from $7.14M to $7.13M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 4.7% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.59M | $4.89M | $8.66M | $8.28M | $9.15M | $13.54M | $14.65M | $16.38M | $10.92M | $9.42M | $10.77M | $4.26M | $4.46M | $14.72M | $5.34M | $7.14M | $6.39M | $5.53M | $9.06M | $7.13M |
| QoQ Change | — | -49.0% | +77.1% | -4.4% | +10.4% | +48.1% | +8.2% | +11.8% | -33.3% | -13.8% | +14.3% | -60.5% | +4.8% | +230.1% | -63.7% | +33.6% | -10.4% | -13.5% | +63.8% | -21.3% |
| YoY Change | — | — | — | — | -4.6% | +177.1% | +69.2% | +97.8% | +19.4% | -30.5% | -26.5% | -74.0% | -59.2% | +56.3% | -50.4% | +67.6% | +43.3% | -62.4% | +69.5% | -0.1% |